153 related articles for article (PubMed ID: 18166785)
1. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.
Lahortiga I; Akin C; Cools J; Wilson TM; Mentens N; Arthur DC; Maric I; Noel P; Kocabas C; Marynen P; Lessin LS; Wlodarska I; Robyn J; Metcalfe DD
Haematologica; 2008 Jan; 93(1):49-56. PubMed ID: 18166785
[TBL] [Abstract][Full Text] [Related]
2. Myeloid tumors accompanying systemic mastocytosis, basophilia, and abnormal platelet-derived growth factor receptor β: A case report.
Li Y; Jing Y; Wan H; Liu D
Medicine (Baltimore); 2021 Feb; 100(8):e24707. PubMed ID: 33663081
[TBL] [Abstract][Full Text] [Related]
3. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
4. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
5. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
[TBL] [Abstract][Full Text] [Related]
6. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
Gallagher G; Horsman DE; Tsang P; Forrest DL
Cancer Genet Cytogenet; 2008 Feb; 181(1):46-51. PubMed ID: 18262053
[TBL] [Abstract][Full Text] [Related]
7. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.
Grand FH; Burgstaller S; Kühr T; Baxter EJ; Webersinke G; Thaler J; Chase AJ; Cross NC
Cancer Res; 2004 Oct; 64(20):7216-9. PubMed ID: 15492236
[TBL] [Abstract][Full Text] [Related]
8. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
9. A 26-Year-Old Female with Systemic Mastocytosis with Associated Myeloid Neoplasm with Eosinophilia and Abnormalities of PDGFRB, t(4;5)(q21;q33).
Brown LE; Zhang D; Persons DL; Yacoub A; Ponnala S; Cui W
Case Rep Hematol; 2016; 2016():4158567. PubMed ID: 27648315
[TBL] [Abstract][Full Text] [Related]
10. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.
Safley AM; Sebastian S; Collins TS; Tirado CA; Stenzel TT; Gong JZ; Goodman BK
Genes Chromosomes Cancer; 2004 May; 40(1):44-50. PubMed ID: 15034867
[TBL] [Abstract][Full Text] [Related]
11. A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).
Iriyama N; Takahashi H; Naruse H; Miura K; Uchino Y; Nakagawa M; Iizuka K; Hamada T; Hatta Y; Nakayama T; Takei M
Mol Genet Genomic Med; 2019 Apr; 7(4):e00591. PubMed ID: 30697976
[TBL] [Abstract][Full Text] [Related]
12. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
[TBL] [Abstract][Full Text] [Related]
13. Acute mast cell leukemia associated with t(4;5)(q21;q33).
Wang RC; Ward D; Dunn P; Chang CC
Hum Pathol; 2017 Sep; 67():198-204. PubMed ID: 28412213
[TBL] [Abstract][Full Text] [Related]
14. Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis.
Agis H; Sotlar K; Valent P; Horny HP
Leuk Res; 2005 Oct; 29(10):1227-32. PubMed ID: 16111540
[TBL] [Abstract][Full Text] [Related]
15. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
16. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms.
Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NC; Grand FH
Br J Haematol; 2010 Jan; 148(2):268-73. PubMed ID: 20085582
[TBL] [Abstract][Full Text] [Related]
17. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.
Baxter EJ; Kulkarni S; Vizmanos JL; Jaju R; Martinelli G; Testoni N; Hughes G; Salamanchuk Z; Calasanz MJ; Lahortiga I; Pocock CF; Dang R; Fidler C; Wainscoat JS; Boultwood J; Cross NC
Br J Haematol; 2003 Jan; 120(2):251-6. PubMed ID: 12542482
[TBL] [Abstract][Full Text] [Related]
18. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.
Pardanani A; Tefferi A
Blood; 2004 Oct; 104(7):1931-9. PubMed ID: 15166033
[TBL] [Abstract][Full Text] [Related]
19. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC
Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377
[TBL] [Abstract][Full Text] [Related]
20. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]